Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen
The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
During 1985–1990 the U.S. National Cancer Institute (NCI) phased out its murine leukemia P388 anticancer drug screening program and developed as the replacement a new in vitro primary screen based upon a diverse panel of human tumor cell lines. For each substance tested, the screen generates a remarkably reproducible and characteristic profile of differential in vitro cellular sensitivity, or lack thereof, across the 60 different cell lines comprising the panel. Several investigational approaches to display, analysis, and interpretation of such profiles and databases, derived from the testing of tens of thousands of substances during the past 4–5 years since the NCI screen became fully operational, have been explored. A variety of useful, practical applications of the in vitro screen have become apparent. As these applications continue to evolve, they are proving to be complementary to diverse other anticancer screening and drug discovery strategies being developed or pursued elsewhere. Reviewed herein are some practical considerations and selected specific examples, particularly illustrating research applications of the NCI screen that may be more broadly applicable to the search for new anticancer drug development leads with novel profiles of antitumor activity and/or mechanisms of action. © 1995 Wiley‐Liss, Inc. This article is a US Government work and, as such, is in the public domain in the United States of America.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, in December 1992, MDA‐MB‐435 was added to the NCI‐60 cell line panel for use in anticancer drug screening, where it was initially described as a “breast” cancer cell line.17”
From Authentication of M14 melanoma cell line proves misidentification of MDA‐MB‐435 breast cancer cell line (2018) · cites this paper as [17]
Citations
Cites
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
Self-citationMonks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Self-citationA Human Cell Line From a Pleural Effusion Derived From a Breast Carcinoma 2
Soule, H. D., Vazquez, J., Long, A., Albert, S., & Brennan, M. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/51.5.1409 · Cited by 2,449
Establishment and characterization of a human prostatic carcinoma cell line (PC-3).
Kaighn, M. E., Ks, N., Ohnuki, Y., Lechner, J. F., & Jones, L. W. (1979) · PubMed · Cited by 2,121
Breast Tumor Cell Lines From Pleural Effusions2
Cailleau, R., Young, R., Olivé, M., & Reeves, W. J. (1974) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/53.3.661 · Cited by 1,015
Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., & Boyd, M. R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1088 · Cited by 967
Self-citationRubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1113 · Cited by 927
Self-citationIsolation of a human prostate carcinoma cell line (DU 145)
Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H., & Paulson, D. F. (1978) · International Journal of Cancer · doi:10.1002/ijc.2910210305 · Cited by 926
Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization
Cailleau, R., Olivé, M., & Cruciger, Q. V. J. (1978) · In Vitro · doi:10.1007/bf02616120 · Cited by 679
Establishment and characterization of a cell line of human breast carcinoma origin
Keydar, I., Chen, L., Karby, S., Weiss, F. R., Delarea, J., Radu, M., Chaitcik, S., & Brenner, H. J. (1979) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(79)90139-7 · Cited by 650
Research works printed but not linked: 6
- Acton EM, 1992, Anticancer specificity of some ellipticinium salts against human brain tumors in vitro, Proc Am Assoc Cancer Res, 33, 488
- Boyd MR, 1986, Accomplishments in Oncology, Vol 1, Cancer Therapy: Where Do We Go From Here?, 68
- Boyd MR, 1989, Cancer: Principles and Practice of Oncology Updates, 1
- Buolamwini JK, 1994, Searching for new molecular targets for therapy of cancer and AIDS: Characterization by 2D protein gel electrophoresis, Proc Am Assoc Cancer Res, 35, 613
- Grever MR, 1994, Status of in vivo evaluations in the NCI anticancer drug discovery program, Proc Am Assoc Cancer Res, 35, 369
- Stinson SF, 1992, Morphologic and immunocytochemical characteristics of human tumor cell lines for use in an anticancer drug screen, Anticancer Res, 12, 1035
Cited by
Items 901–1,000 of 1,000
Khalil, A. F., El-Moselhy, T. F., El-Bastawissy, E. A., Abdelhady, R., Younis, N. S., & El‐Hamamsy, M. H. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2157411 · Cited by 17
Amin, N. H., El‐Saadi, M. T., Abdel‐Fattah, M. M., Mohammed, A. A., & Said, E. G. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106496 · Cited by 17
Husseiny, E. M., Abulkhair, H. S., El‐Hddad, S. S. A., Osama, N., & El‐Zoghbi, M. S. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0139 · Cited by 17
Reda, N., ElShewy, A. M., El‐Askary, H. I., Mohamed, K. O., & Helwa, A. A. (2023) · RSC Advances · doi:10.1039/d3ra06088h · Cited by 18
Bussey, K. J., & Demeure, M. J. (2009) · Future Oncology · doi:10.2217/fon.09.45 · Cited by 17
Ahsan, M. J., Hassan, M. Z., Jadav, S. S., Geesi, M. H., Bakht, M. A., Riadi, Y., Salahuddin, S., Akhtar, M. S., Mallick, M. N., & Akhter, M. H. (2020) · Letters in Organic Chemistry · doi:10.2174/15701786otc3zmjcdtcvy · Cited by 17
Коbylinska, L. I., Ivasechko, I., Skorokhyd, N. R., Panchuk, R. R., Riabtseva, A., Mitina, N., Zaichenko, A., Lesyk, R., Zimenkovsky, B. S., Stoika, R. S., et al. (2019) · Nanoscale Research Letters · doi:10.1186/s11671-019-2945-7 · Cited by 17
Sm-Catalyzed Synthesis and Biological Activity of Acyclic and Cyclic Azadiperoxides
Makhmudiyarova, N. N., Rakhimov, R. S., Tyumkina, T. V., Meshcheryakova, E. S., Ибрагимов, А. Г., & Dzhemilev, U. M. (2019) · Russian Journal of Organic Chemistry · doi:10.1134/s1070428019050075 · Cited by 17
Yatam, S., Jadav, S. S., Gundla, K. P., Paidikondala, K., Ankireddy, A. R., Babu, B. N., Ahsan, M. J., & Gundla, R. (2019) · ChemistrySelect · doi:10.1002/slct.201902972 · Cited by 18
Synthesis and Anticancer Activity of Isatin, Oxadiazole and 4-Thiazolidinone Based Conjugates
Lelyukh, M. I., Havrylyuk, D., & Lesyk, R. (2015) · Chemistry & Chemical Technology · doi:10.23939/chcht09.01.029 · Cited by 17
Pyrih, A., Jaskólski, M., Gzella, A. K., & Lesyk, R. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.129059 · Cited by 17
Identification of proteasome inhibitors using analysis of gene expression profiles
Mofers, A., Selvaraju, K., Gubat, J., D’Arcy, P., & Linder, S. T. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173709 · Cited by 17
Kazakova, O. B., Rubanik, L., Smirnova, I. E., Полещук, Н. Н., Petrova, A., Kapustsina, Y., Байкова, И. П., Tret’yakova, E. V., & Khusnutdinova, E. F. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02741-6 · Cited by 17
Hassan, A. Y., Abou‐Amra, E. S., & El‐Sebaey, S. A. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.134930 · Cited by 17
BIOSYNTHETIC PRODUCTS FOR ANTICANCER DRUG DESIGN AND TREATMENT: THE BRYOSTATINS
Pettit, G. R., Herald, C. L., & Hogan, F. (2002) · Elsevier eBooks · doi:10.1016/b978-012072651-6/50013-9 · Cited by 20
Gangjee, A., Zaware, N., Devambatla, R. K. V., Raghavan, S., Westbrook, C., Dybdal‐Hargreaves, N. F., Hamel, E., & Mooberry, S. L. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.12.010 · Cited by 17
Slawinski, J. J., Żołnowska, B., Orlewska, C., & Chojnacki, J. (2012) · Monatshefte für Chemie - Chemical Monthly · doi:10.1007/s00706-012-0849-7 · Cited by 17
Dual IGF-1R/SRC inhibitors based on a N′-aroyl-2-(1H-indol-3-yl)-2-oxoacetohydrazide structure
Schmidt, S., Preu, L., Lemcke, T., Totzke, F., Schächtele, C., Kubbutat, M. H. G., & Kunick, C. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.03.065 · Cited by 17
Taher, A. T., & Mohammed, L. W. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0081-y · Cited by 17
Stojković, M. R., Piantanida, I., Kralj, M., Marjanović, M., Žinić, M., Pawlica, D., & Eilmes, J. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.11.034 · Cited by 17
Structure–activity relationships of side-chain modified didemnins
Ding, X., Vera, M. D., Liang, B., Zhao, Y., Leonard, M. S., & Joullié, M. M. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00638-7 · Cited by 17
Kovačević, M., Molčanov, K., Radošević, K., Srček, V. G., Roca, S., Čače, A., & Barišić, L. (2014) · Molecules · doi:10.3390/molecules190812852 · Cited by 17
Machicado, C., Soto, M. P., Timoteo, O. S., Vaisberg, A., Pajuelo, M. J., Ortiz, P., & Marcos, L. A. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02373-18 · Cited by 17
Tret’yakova, E. V., Salimova, E. V., Parfenova, L. V., Yunusbaeva, M. M., Dzhemileva, L. U., D'yakonov, V. A., & Dzhemilev, U. M. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190404100846 · Cited by 18
Hutchinson, I. S., McCarroll, A. J., Heald, R. A., & Stevens, M. F. G. (2004) · Organic & Biomolecular Chemistry · doi:10.1039/b310796p · Cited by 17
Krištafor, V., Raić‐Malić, S., Cetina, M., Kralj, M., Šuman, L., Pavelić, K., Balzarini, J. M., Clercq, E. D., & Mintas, M. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.07.033 · Cited by 17
Trafalis, D. T., Camoutsis, C., & Papageorgiou, A. (2005) · Melanoma Research · doi:10.1097/00008390-200508000-00007 · Cited by 17
El‐Sherbeny, M. A. (2000) · Archiv der Pharmazie · doi:10.1002/1521-4184(200010)333:10<323::aid-ardp323>3.0.co;2-u · Cited by 17
Insuasty, D., Robledo, S. M., Vélez, I. D., Cuervo, P. A., Braulio Insuasty, O., Jairo Quiroga, P., Nogueras, M., Cobo, J., & Abonía, R. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.024 · Cited by 17
Evaluation of the role of caspase-6 in anticancer drug-induced apoptosis
Loegering, D. A., Ruchaud, S., Earnshaw, W. C., & Kaufmann, S. H. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401791 · Cited by 17
Singh, P., Mittal, A., & Kumar, S. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.04.004 · Cited by 18
Experimental Antitumour Activity of S 16020-2 in a Panel of Human Tumours
Kraus‐Berthier, L., Guilbaud, N., Jan, M., Saint-Dizier, D., Rouillon, M. H., Burbridge, M. F., Pierré, A., & Atassi, G. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00232-3 · Cited by 17
Bouzas, A., de Cedrón, M. G., Colmenarejo, G., Laparra, J. M., Moreno‐Rubio, J., Montoya, J. J., Reglero, G., Casado, E., Tabarés, B., Sereno, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1046369 · Cited by 18
Pamarthy, D., Behera, S. K., Swain, S., Yadav, S., Suresh, S., Jain, N., & Bhadra, M. P. (2023) · Drug Development Research · doi:10.1002/ddr.22059 · Cited by 16
Mohamed‐Ezzat, R. A., & Elgemeie, G. H. (2024) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2024.2341406 · Cited by 16
Elgammal, W. E., Shaban, S. S., Eliwa, E. M., Halawa, A. H., El-Gilil, S. M. A., Hassan, R. A., Abdou, A. M., Elhagali, G. A. M., & Reheim, M. A. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2342668 · Cited by 16
Faggal, S. I., El‐Dash, Y., Sonousi, A. S. M., Abdou, A. M., & Hassan, R. A. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00462k · Cited by 16
Kryshchyshyn‐Dylevych, A., Atamanyuk, D. V., Kaminskyy, D. V., Grellier, P., & Lesyk, R. (2017) · Biopolymers and Cell · doi:10.7124/bc.00094f · Cited by 16
Jun, J. H., Kumar, V., Dexheimer, T. S., Wedlich, I., Nicklaus, M. C., Pommier, Y. G., & Malhotra, S. V. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.10.017 · Cited by 16
Selected 5-amino-1-aryl-1H-1,2,3-triazole scaffolds as promising antiproliferative agents
Pokhodylo, N. T., Shyyka, O. Y., Finiuk, N. S., & Stoika, R. S. (2020) · The Ukrainian Biochemical Journal · doi:10.15407/ubj92.05.023 · Cited by 16
Gobinath, P., Packialakshmi, P., Vijayakumar, K., Abdellattif, M. H., Shahbaaz, M., Idhayadhulla, A., & Surendrakumar, R. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.637989 · Cited by 17
Pokhodylo, N. T., Finiuk, N. S., Klyuchivska, O., Tupychak, M., Matiychuk, V. S., Goreshnik, E., & Stoika, R. S. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114633 · Cited by 18
Ciftci, H. I., Sever, B., Bayrak, N., Yıldız, M., Yıldırım, H., Tateishi, H., Otsuka, M., Fujita, M., & Tuyun, A. F. (2022) · Pharmaceuticals · doi:10.3390/ph15101266 · Cited by 16
Szafrański, K., & Slawinski, J. J. (2015) · Molecules · doi:10.3390/molecules200712029 · Cited by 16
Antitumor cell activity in vitro by myristoylated-peptide
Ourth, D. D. (2011) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2011.02.015 · Cited by 16
Wong, C. C., Sagineedu, S. R., Sumon, S. H., Sidik, S. M., Phillips, R. M., Lajis, N. H., & Stanslas, J. (2014) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2014.07.016 · Cited by 16
Pellynol I, A New Cytotoxic Polyacetylene from the SpongePellinasp
Rashid, M. A., Gustafson, K. R., & Boyd, M. R. (2000) · Natural product letters · doi:10.1080/10575630008043772 · Cited by 16
Self-citationGangjee, A., Pavana, R. K., Li, W., Hamel, E., Westbrook, C., & Mooberry, S. L. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0816-3 · Cited by 16
ChemGPS‐NP Mapping of Chemical Compounds for Prediction of Anticancer Mode of Action
Rosén, J., Rickardson, L., Backlund, A., Gullbo, J., Bohlin, L., Larsson, R., & Gottfries, J. (2009) · QSAR & Combinatorial Science · doi:10.1002/qsar.200810162 · Cited by 18
Phenotypical alterations induced by glucocorticoids resistance in RPMI 8226 human myeloma cells
Genty, V., Dine, G., & Dufer, J. (2003) · Leukemia Research · doi:10.1016/j.leukres.2003.08.009 · Cited by 20
Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells
Kim, K., Lange, T. S., Singh, R. K., & Brard, L. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-72 · Cited by 16
On the mechanism underlying calcein-induced cytotoxicity
Liminga, G., Jönsson, B., Nygren, P., & Larsson, R. L. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00655-x · Cited by 16
Antiproliferative activities of halogenated pyrrolo[3,2-d]pyrimidines
Temburnikar, K. W., Ross, C. R., Wilson, G. M., Balzarini, J. M., Cawrse, B. M., & Seley‐Radtke, K. L. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.06.025 · Cited by 16
Synthesis of cytotoxic cembranolide analogues via acid-induced opening of oxiranes
Rodríguez, A. D., Piña, I. C., Acosta, A. L., & Barnes, C. L. (2001) · Tetrahedron · doi:10.1016/s0040-4020(00)01000-0 · Cited by 16
Appel, J. R., Johnson, J., Narayanan, V. L., & Houghten, R. A. (1998) · Molecular Diversity · doi:10.1023/a:1026441400053 · Cited by 16
Dhar, S., Gullbo, J., Csóka, K., Eriksson, E., Nilsson, K., Nickel, P., Larsson, R., & Nygren, P. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00024-1 · Cited by 16
Sun, R., Yang, D., Hu, Y. G., Hao, Q., Li, X., & Zhang, S. (2023) · Biomedical Optics Express · doi:10.1364/boe.495311 · Cited by 15
Abdelaal, H. I., Mohamed, A. R., Abo-Ashour, M. F., Giovannuzzi, S., Fahim, S. H., Abdel‐Aziz, H. A., Supuran, C. T., & Abou‐Seri, S. M. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107759 · Cited by 15
Mulcahy, S. P., Woo, C. M., Ding, W., Ellestad, G. A., & Herzon, S. B. (2011) · Chemical Science · doi:10.1039/c2sc00854h · Cited by 15
Synthesis and Cytotoxicity of A-Azepanodammaradiene
Smirnova, I. E., Petrova, A. V., & Kazakova, O. B. (2019) · Chemistry of Natural Compounds · doi:10.1007/s10600-019-02838-w · Cited by 15
Grant, C. V., Cai, S., Risinger, A. L., Liang, H., O’Keefe, B. R., Doench, J. G., Cichewicz, R. H., & Mooberry, S. L. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.0c00642 · Cited by 15
Singh, R. P., Kumar, R., Pandrala, M., Kaur, P., Gupta, S., Tailor, D., Malhotra, S. V., & Salunke, D. B. (2021) · Archiv der Pharmazie · doi:10.1002/ardp.202000393 · Cited by 15
Insuasty, D., García, S., Abonía, R., Braulio Insuasty, O., Jairo Quiroga, P., Nogueras, M., Cobo, J., Borosky, G. L., & Laali, K. K. (2021) · Archiv der Pharmazie · doi:10.1002/ardp.202100094 · Cited by 15
Synthesis and biological studies of oxoquinolines: Experimental and theoretical investigations
Bakht, M. A., Azam, F., Ali, A., Thomas, R., Pooventhiran, T., Ali, A., & Ahsan, M. J. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131509 · Cited by 15
Design, Synthesis of Analgesics and Anticancer of Some New Derivatives of Benzimidazole
Sakr, H. M., Ayyad, R. R. A., Mahmoud, K., Mansour, A. M., & Ahmed, A. G. (2021) · International Journal of Organic Chemistry · doi:10.4236/ijoc.2021.113011 · Cited by 15
El‐Hussieny, M., El‐Sayed, N. F., Fouad, M. A., & Ewies, E. F. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105421 · Cited by 15
Pokhodylo, N. T., Finiuk, N. S., Klyuchivska, O., Stoika, R. S., Matiychuk, V. S., & Obushak, M. D. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115126 · Cited by 15
Polovkovych, S. V., Karkhut, A., Марінцова, Н. Г., Lesyk, R., Zimenkovsky, B. S., & Novikov, V. P. (2013) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.890 · Cited by 15
Design, Synthesis and Cytotoxic Evaluation of o-Carboxamido Stilbene Analogues
Azmi, M. N., Din, M., Kee, C. H., Suhaimi, M., Ping, A., Ahmad, K., Nafiah, M. A., Thomas, N. V., Mohamad, K., Hoong, L., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141223369 · Cited by 15
Kamal, Ä., Khan, M. N. A., Srikanth, Y. V. V., & Rajesh, S. V. C. R. N. C. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00815.x · Cited by 15
Gabr, M. T., El‐Gohary, N. S., El‐Bendary, E. R., & El‐Kerdawy, M. M. (2014) · EXCLI journal · Cited by 18
Synthesis and Cytotoxicity of Indole Derivatives of Betulin, Erythrodiol, and Uvaol
Khusnutdinova, E. F., Petrova, A. V., Николаевна, А. Г., Kukovinets, O. S., & Kazakova, O. B. (2018) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162018030081 · Cited by 15
Abonía, R., Laali, K. K., Somu, D. R., Bunge, S. D., & Wang, E. C. (2019) · ChemMedChem · doi:10.1002/cmdc.201900640 · Cited by 15
Cytotoxic Potential of a-Azepano- and 3-Amino-3,4-SeCo-Triterpenoids
Kazakova, O. B., Smirnova, I. E., Tret’yakova, E. V., Csük, R., Hoenke, S., & Fischer, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041714 · Cited by 15
Antitumor properties of thiazolo[4,5-b]pyridin-2-one derivatives
(2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac104.944950 · Cited by 15
Bioactive constituents of the family differocarpaceae
Seo, E. K., & Kinghorn, A. D. (2000) · Studies in natural products chemistry · doi:10.1016/s1572-5995(00)80137-4 · Cited by 15
Cokol, M. (2013) · Current Drug Discovery Technologies · doi:10.2174/1570163811310020003 · Cited by 15
Kayarmar, R., Nagaraja, G. K., Bhat, M., Naik, P., Rajesh, K. P.-G., Shetty, S. R., & Arulmoli, T. (2013) · Medicinal Chemistry Research · doi:10.1007/s00044-013-0885-9 · Cited by 15
Mariggiò, M. A., Cafaggi, S., Ottone, M., Parodi, B., Vannozzi, M. O., Mandys, V., & Viale, M. (2003) · Investigational New Drugs · doi:10.1023/b:drug.0000006170.38419.c9 · Cited by 15
Singh, P., Mittal, A., Kaur, S., & Kumar, S. (2008) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2007.12.017 · Cited by 15
Dioncophylline A, the Principal Cytotoxin fromAncistrocladus letestui
Hallock, Y. F., Hughes, C. B., Cardellina, J. H., Schäffer, M., Gulden, K.-P., Bringmann, G., & Boyd, M. R. (1995) · Natural product letters · doi:10.1080/10575639508043177 · Cited by 15
Self-citationBabić, Ž. L., Crkvenčić, M., Rajić, Z., Mikecin, A., Kralj, M., Balzarini, J. M., Petrova, M., Vanderleyden, J., & Zorc, B. (2012) · Molecules · doi:10.3390/molecules17011124 · Cited by 15
Ahsan, M. J. (2016) · ChemistrySelect · doi:10.1002/slct.201600465 · Cited by 15
NATURAL PRODUCTS AS PHARMACEUTICALS AND SOURCES FOR LEAD STRUCTURES
Newman, D. J., Cragg, G. M. L., & Kingston, D. G. I. (2003) · Elsevier eBooks · doi:10.1016/b978-012744481-9/50010-6 · Cited by 15
Ikediobi, O. N., Reimers, M., Durinck, S., Blower, P. E., Futreal, P. A., Stratton, M. R., & Weinstein, J. N. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2308 · Cited by 15
The reaction of di-n-butyltin oxide with hexafluoro-2,2-bis(4-carboxyphenyl)propane
Willem, R., Dalil, H., Biesemans, M., Martins, J. C., & Gielen, M. (1999) · Applied Organometallic Chemistry · doi:10.1002/(sici)1099-0739(199908)13:8<605::aid-aoc874>3.0.co;2-8 · Cited by 15
Gao, J. P., Reibenspies, J. H., & Martell, A. E. (2003) · Organic & Biomolecular Chemistry · doi:10.1039/b308358f · Cited by 15
Jannuzzi, A. T., Yıldız, M., Bayrak, N., Yıldırım, H., Shilkar, D., Jayaprakash, V., & Tuyun, A. F. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109673 · Cited by 14
Bromodomain Inhibitor JQ1 Provides Novel Insights and Perspectives in Rhabdomyosarcoma Treatment
Marchesi, I., Fais, M., Fiorentino, F., Bordoni, V., Sanna, L., Zoroddu, S., & Bagella, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073581 · Cited by 14
Zonjić, I., Stojković, M. R., Crnolatac, I., Paić, A. T., Pšeničnik, S., Vasilev, A. A., Kandinska, M. I., Mondeshki, M., Baluschev, S. B., Landfester, K., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105999 · Cited by 14
Sayed, M. T., Elsharbasy, S. A., & Abdel‐Aziem, A. (2023) · Polycyclic aromatic compounds · doi:10.1080/10406638.2023.2201458 · Cited by 14
Design, synthesis, and evaluation of new benzimidazole thiourea derivatives as antitumor agents
Aboutaleb, M. H., El‐Gohary, N. S., Ghabbour, H. A., & El‐Kerdawy, M. M. (2023) · Archiv der Pharmazie · doi:10.1002/ardp.202300269 · Cited by 14
Ahmed, N., Mohamed, M. S., Awad, S. M., El-tawab, N. A. A., Gaballah, M. S. A., & Said, A. M. (2024) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2024.2304625 · Cited by 15
Lo, Y., Lin, I., Lin, C., Hsu, C., Yang, S., Lin, S., & Wu, M. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.04.024 · Cited by 14
Synthesis, docking and in vitro anticancer evaluation of some new benzopyrone derivatives
El-Ansary, S. L., Hussein, M. M., Rahman, D. E. A., & Ghany, L. M. A. A. (2014) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2014.02.003 · Cited by 14
Exploration of (hetero)aryl Derived Thienylchalcones for Antiviral and Anticancer Activities
Patil, V., Patil, S. A., Patil, R., Bugarin, A., Beaman, K. D., & Patil, S. A. (2018) · Medicinal Chemistry · doi:10.2174/1573406414666180524074648 · Cited by 14
Kil, Y., Risinger, A. L., Petersen, C. L., Liang, H., Grkovic, T., O’Keefe, B. R., Mooberry, S. L., & Cichewicz, R. H. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00896 · Cited by 14
Chaban, T. I., Matiichuk, Y., Horishny, V. Y., Chaban, I. G., & Matiychuk, V. S. (2020) · Russian Journal of Organic Chemistry · doi:10.1134/s1070428020050139 · Cited by 14
In vitro evaluation of estrogenic, antiestrogenic and antitumor effects of amentoflavone
Aliyev, A. T., Ozcan, S., Akdemir, A., & Gürer-Orhan, H. (2021) · Human & Experimental Toxicology · doi:10.1177/0960327121999454 · Cited by 14
Ewida, M. A., Ewida, H. A., Ahmed, M. S., Allam, H. A., El-Bagary, R. I., George, R. F., Georgey, H. H., & El‐Subbagh, H. I. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105205 · Cited by 14
Metadata
- Authors
- Boyd, M. R., & Paull, K. D.
- Affiliations
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (US)
- Corresponding author
- Boyd, Michael R.
- ORCID
- Boyd, Michael R.
- Venue
- Drug Development Research
- Publisher
- Wiley
- Published
- 1995-02
- Volume
- 34
- Issue
- 2
- Pages
- 91-109
- ISSN
- 0272-4391 (ISSN-L)
- 1098-2299
- OpenAlex
- W2118909720
- Cited by
- 1,572
- References
- 40
- Citations by year
- 2026: 28 · 2025: 57 · 2024: 79 · 2023: 58 · 2022: 68 · 2021: 81 · 2020: 74 · 2019: 51 · 2018: 58 · 2017: 39 · 2016: 56 · 2015: 61 · 2014: 78 · 2013: 84 · 2012: 79
- FWCI
- 30.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Development Research (publishedVersion, public-domain)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- anticancer drug discovery, human cancer cell lines, anticancer activity, lead compound identification, mechanism of action
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.